Biotechnology company MorphoSys AG (FRA: MOR) has partnered with privately-held fellow Germany-based Immatics Biotechnologies to develop antibody-based treatments for cancer.
The companies in a joint statement said they will pay each other milestones based on their respective development progress as well as royalties on marketed products. However, no financial details were disclosed.
Marlies Sproll, chief scientific officer of MorphoSys, said: “This alliance opens up the intracellular target space for us and thus complements the therapeutic approaches we use in other oncology programs. We believe this collaboration will create several unique product opportunities for us based on truly differentiated compounds.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze